Empagliflozin groups showed smaller atherosclerotic plaque areas in the aortic arch/valve, and lower insulin resistance and inflammation markers (TNF-, interleukin [IL]-6, monocyte chemoattractant protein-1, etc - DHFR inhibitors in non-small cell lung cancer

Empagliflozin groups showed smaller atherosclerotic plaque areas in the aortic arch/valve, and lower insulin resistance and inflammation markers (TNF-, interleukin [IL]-6, monocyte chemoattractant protein-1, etc.) … Continue reading Empagliflozin groups showed smaller atherosclerotic plaque areas in the aortic arch/valve, and lower insulin resistance and inflammation markers (TNF-, interleukin [IL]-6, monocyte chemoattractant protein-1, etc